Trial Profile
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab (Anti-Pd-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 25 Apr 2024
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary)
- Indications Carcinoma; Head and neck cancer; Squamous cell cancer
- Focus Registrational; Therapeutic Use
- Acronyms IMvoke010
- Sponsors Roche
- 25 Apr 2024 This trial has been completed in Germany (Global end date: 6 Mar 2024).
- 24 Apr 2024 This trial has been completed in Portugal, according to European Clinical Trials Database record.
- 29 Mar 2024 This trial has been completed in France, as per European Clinical Trials Database record.